Shenzhen Lifotronic Technology Co (688389) - Total Assets
Based on the latest financial reports, Shenzhen Lifotronic Technology Co (688389) holds total assets worth CN¥2.53 Billion CNY (≈ $369.58 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Shenzhen Lifotronic Technology Co total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Shenzhen Lifotronic Technology Co - Total Assets Trend (2016–2025)
This chart illustrates how Shenzhen Lifotronic Technology Co's total assets have evolved over time, based on quarterly financial data. Check 688389 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Shenzhen Lifotronic Technology Co - Asset Composition Analysis
Current Asset Composition (December 2025)
Shenzhen Lifotronic Technology Co's total assets of CN¥2.53 Billion consist of 69.7% current assets and 30.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 56.0% |
| Accounts Receivable | CN¥173.64 Million | 6.2% |
| Inventory | CN¥183.04 Million | 6.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥99.72 Million | 3.6% |
| Goodwill | CN¥23.16 Million | 0.8% |
Asset Composition Trend (2016–2025)
This chart illustrates how Shenzhen Lifotronic Technology Co's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Shenzhen Lifotronic Technology Co market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shenzhen Lifotronic Technology Co's current assets represent 69.7% of total assets in 2025, a decrease from 88.8% in 2016.
- Cash Position: Cash and equivalents constituted 56.0% of total assets in 2025, down from 82.5% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, unchanged from 3.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 6.5% of total assets.
Shenzhen Lifotronic Technology Co Competitors by Total Assets
Key competitors of Shenzhen Lifotronic Technology Co based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$139.55 Million |
|
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351
|
China | CN¥2.00 Billion |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
INKON Life Technology Co Ltd
SHE:300143
|
China | CN¥4.17 Billion |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $90.55 Million |
|
Shanghai General Healthy Information and Technology Co. Ltd.
SHG:605186
|
China | CN¥1.59 Billion |
Shenzhen Lifotronic Technology Co - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.34 | 2.75 | 5.53 |
| Quick Ratio | 3.86 | 2.50 | 4.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.27 Billion | CN¥1.30 Billion | CN¥773.26 Million |
Shenzhen Lifotronic Technology Co - Advanced Valuation Insights
This section examines the relationship between Shenzhen Lifotronic Technology Co's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.60 |
| Latest Market Cap to Assets Ratio | 0.23 |
| Asset Growth Rate (YoY) | -2.9% |
| Total Assets | CN¥2.81 Billion |
| Market Capitalization | $657.73 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shenzhen Lifotronic Technology Co's assets below their book value (0.23x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Shenzhen Lifotronic Technology Co's assets decreased by 2.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Shenzhen Lifotronic Technology Co (2016–2025)
The table below shows the annual total assets of Shenzhen Lifotronic Technology Co from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.81 Billion ≈ $411.12 Million |
-2.94% |
| 2024-12-31 | CN¥2.89 Billion ≈ $423.56 Million |
+24.16% |
| 2023-12-31 | CN¥2.33 Billion ≈ $341.15 Million |
+28.06% |
| 2022-12-31 | CN¥1.82 Billion ≈ $266.40 Million |
+23.47% |
| 2021-12-31 | CN¥1.47 Billion ≈ $215.76 Million |
+14.34% |
| 2020-12-31 | CN¥1.29 Billion ≈ $188.70 Million |
+9.38% |
| 2019-12-31 | CN¥1.18 Billion ≈ $172.52 Million |
+45.21% |
| 2018-12-31 | CN¥811.93 Million ≈ $118.81 Million |
+14.29% |
| 2017-12-31 | CN¥710.40 Million ≈ $103.95 Million |
+42.79% |
| 2016-12-31 | CN¥497.52 Million ≈ $72.80 Million |
-- |
About Shenzhen Lifotronic Technology Co
Shenzhen Lifotronic Technology Co., Ltd. research, develops, manufactures, and markets medical devices for diagnostics, therapy, clinical medicine, skin, and human health related purposes in China. The company offers IVD products, such as HPLC, ECLIA, and hematology system; rapid test, molecular and POCT diagnostics. It also offers therapeutic products comprising respiratory and ICU, and wound ca… Read more